D Williams Parsons
Overview
Explore the profile of D Williams Parsons including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
15998
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fiorica P, Golmard L, Kim J, Bao R, Lin F, Roy A, et al.
Clin Cancer Res
. 2025 Feb;
PMID: 39992227
Purpose: DROSHA, DGCR8, and DICER1 regulate microRNA biogenesis and are commonly mutated in cancer. Whereas DGCR8 and DICER1 germline pathogenic variants (GPVs) cause autosomal dominant tumor predisposition, no association between...
2.
Desrosiers-Battu L, Lee J, Tarasiewicz I, Gilbert A, Galvan E, Singh A, et al.
Cancer Genet
. 2025 Feb;
292-293:106-110.
PMID: 39985924
Meningiomas are the most common primary brain tumors in adults but much less frequent in children. Many subtypes exist, including anaplastic (malignant) meningioma, which accounts for less than 20% of...
3.
Hirschi O, Felker S, Rednam S, Vallance K, Parsons D, Roy A, et al.
Genet Med Open
. 2024 Dec;
2():101850.
PMID: 39669609
Purpose: Clinical variant analysis pipelines likely have poor sensitivity to the effects on splicing from variants beyond 10 to 20 bases of exon-intron boundaries. Here, we demonstrate the value of...
4.
Macy M, Mody R, Reid J, Piao J, Saguilig L, Alonzo T, et al.
JCO Precis Oncol
. 2024 Sep;
8():e2400418.
PMID: 39298716
Purpose: The National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice trial assigned patients age 1-21 years with relapsed or refractory solid tumors, lymphomas, and histiocytic disorders to...
5.
Desrosiers-Battu L, Wang T, Reuther J, Miles G, Dai H, Jo E, et al.
JCO Precis Oncol
. 2024 Sep;
8():e2400187.
PMID: 39259914
Purpose: To evaluate the relative diagnostic yield of clinical germline genomic tests in a diverse pediatric cancer population. Patients And Methods: The KidsCanSeq study enrolled pediatric cancer patients across six...
6.
Vo K, Sabnis A, Williams P, Roy-Chowdhuri S, Patton D, Coffey B, et al.
JCO Precis Oncol
. 2024 Jun;
8:e2400103.
PMID: 38935895
Purpose: The National Cancer Institute-Children's Oncology Group (NCI-COG) Pediatric MATCH trial assigns patients age 1-21 years with refractory malignancies to phase II treatment arms of molecularly targeted therapies on the...
7.
Nelson M, Kim A, Williams P, Roy-Chowdhuri S, Patton D, Coffey B, et al.
Oncologist
. 2024 Jun;
29(8):723-e1093.
PMID: 38873934
Background: This is a phase II subprotocol of the NCI-COG Pediatric MATCH study evaluating vemurafenib, a selective oral inhibitor of BRAF V600 mutated kinase, in patients with relapsed or refractory...
8.
Mangum R, Lin F, Parsons D
J Pediatr Hematol Oncol
. 2024 Jun;
46(5):262-271.
PMID: 38857189
Precision oncology incorporates comprehensive genomic profiling into the individualized clinical care of pediatric cancer patients. In recent years, comprehensive pan-cancer analyses have led to the successful implementation of genomics-based pediatric...
9.
Lin F, Stuckert A, Tat C, White M, Ruggieri L, Zhang H, et al.
J Clin Oncol
. 2024 May;
42(23):2769-2779.
PMID: 38771986
Purpose: T cells modified with chimeric antigen receptors (CARTs) have demonstrated efficacy for hematologic malignancies; however, benefit for patients with CNS tumors has been limited. To enhance T cell activity...
10.
Gutierrez A, Robinson J, Smith H, Desrosiers-Battu L, Scollon S, Canfield I, et al.
Genet Med
. 2024 May;
26(8):101168.
PMID: 38767058
Purpose: Professional guidelines recommend engaging adolescents and young adults (AYAs) in medical decision making (DM), including whether to undergo genomic sequencing (GS). We explored DM around GS and attitudes after...